<DOC>
	<DOCNO>NCT01990144</DOCNO>
	<brief_summary>The purpose study evaluate feasibility efficacy rituximab-bendamustine ( R-B ) combination elderly patient affect diffuse large B-cell lymphoma define frail accord CGA .</brief_summary>
	<brief_title>Rituximab Plus Bendamustine Front Line Treatment Frail Elderly ( &gt; 70 Years ) Patients With DLBCL : Phase II Multicenter Study FIL</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Histologically proven CD20 positive diffuse large Bcell nonHodgkin 's lymphoma Age &gt; 70 year No previous treatment FRAIL patient define follow ( see Appendices BE ) Age &gt; 80 year UNFIT profile , i.e . ADL &gt; 5 residual function IADL &gt; 6 residual function CIRS 58 comorbidities grade 2 Age &lt; 80 year ADL &lt; 4 residual function , IADL &lt; 5 residual function , CIRS : 1 comorbidity grade 34 , &gt; 8 comorbidities grade 2 Life expectancy &gt; 6 month Written inform consent Accessibility patient treatment follow History malignancy within 5 year prior study entry except adequately treat carcinoma situ cervix basal squamous cell skin cancer Previous exposure cytotoxic agent Suspect clinical evidence CNS involvement lymphoma HBsAg , HCV HIV positivity ; HBcAb positivity accept concomitant treatment Lamivudine AST /ALT &gt; twice upper normal range ; bilirubin &gt; twice upper normal range ; serum creatinine &gt; 2.5 mg /dl Evidence severe active acute chronic infection Concurrent comorbid medical condition might exclude administration full dose chemotherapy Senile dementia Any coexist medical psychological condition would preclude participation study compromise ability give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>